Selonsertib-impurities | Pharmaffiliates

Selonsertib

Selonsertib is being developed by Gilead Sciences for the oral treatment of diabetic nephropathies, pulmonary arterial hypertension, kidney disorders and liver disorders.Reference standards of Selonsertib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Selonsertib - API Standards 
    [catalogue_number] => PA 46 41000
    [category_ids] => ,80,75,89,78,70,82,
    [chemical_name] => 
    [weight] => 445.50
    [form] => C24H24FN7O
    [cas] => 1448428-04-3
    [pslug] => 1448428-04-3-selonsertib-api-pa4641000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 46 41000

Selonsertib - API Standards


  • Catalogue No.:PA 46 41000

  • CAS :

    1448428-04-3

  • Molecular Formula : C24H24FN7O

  • Molecular Weight : 445.50